Renal toxicity associated with tenofovir use

Bibliography

• Vandercam B, Moreau M, Goffin E, Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999;29(4):948-9
   PubMed Web of Science ®Google Scholar
• Gagnon R, Tecimer S, Watters A, Tsoukas C. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000;36(3):507-15
   PubMed Web of Science ®Google Scholar
• Gallant J, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis 2003;37(7):944-50
   PubMed Web of Science ®Google Scholar
• Karras A, Lafaurie M, Furco A, Tenofovir-related nephrotoxicity in HIV-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36(8):1070-3
   PubMed Web of Science ®Google Scholar
• James C, Steinhaus M, Szabo S, Dressier R. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004;24(3):415-8
   PubMed Web of Science ®Google Scholar
• Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect 2005;51(2):E61-5
   PubMedGoogle Scholar
• Young B, Buchacz K, Moorman A, ; HIV Outpatient Study (HOPS) Investigators. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. AIDS Patient Care STDS 2009;23(8):589-92
   PubMed Web of Science ®Google Scholar
• Izzedine H, Baumelou A, Deray G. Acute renal failure in HIV patients. Nephrol Dial Transplant 2007;22(10):2757-62
   PubMed Web of Science ®Google Scholar
• Cihlar T, Ho E, Lin D, Mulato A. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001;20(4-7):641-8
   PubMed Web of Science ®Google Scholar
• Ray A, Cihlar T, Robinson K, Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50(10):3297-304
   PubMed Web of Science ®Google Scholar
• Mallants R, Van OK, Van V, Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 2005;35(10-11):1055-66
   PubMed Web of Science ®Google Scholar
• Miller D. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 2001;299(2):567-74
   PubMed Web of Science ®Google Scholar
• Imaoka T, Kusuhara H, Adachi M, Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007;71(2):619-27
   PubMed Web of Science ®Google Scholar
• van Aubel R, Smeets P, Peters J, The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002;13(3):595-603
   PubMedGoogle Scholar
• van Aubel R, Smeets P, van den Heuvel J, Russel F. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 2005;288(2):F327-33
   PubMed Web of Science ®Google Scholar
• Cihlar T, Birkus G, Greenwalt D, Hitchcock M. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res 2002;54(1):37-45
   PubMed Web of Science ®Google Scholar
• Birkus G, Hitchcock M, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46(3):716-23
   PubMed Web of Science ®Google Scholar
• Cote H, Magil A, Harris M, Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006;11(1):79-86
   PubMed Web of Science ®Google Scholar
• Kohler J, Hosseini S, Hoying-Brandt A, Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009;89(5):513-9
   PubMed Web of Science ®Google Scholar
• Lebrecht D, Venhoff AC, Kirschner J, Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J Acquir Immune Defic Syndr 2009;51(3):258-63
   PubMed Web of Science ®Google Scholar
• Weiss J, Theile D, Ketabi-Kiyanvash N, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007;35(3):340-4
   PubMed Web of Science ®Google Scholar
• Liborio A, Andrade L, Pereira L, Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney Int 2008;74(7):910-18
   PubMed Web of Science ®Google Scholar
• Gallant J, Staszewski S, Pozniak A, Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292(2):191-201
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot J, Vittecoq D, Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005;20(4):743-6
   PubMed Web of Science ®Google Scholar
• Arribas J, Pozniak A, Gallant J, Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47(1):74-8
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Gatell J, Chronic renal failure among HIV-1-infected patients. AIDS 2007;21(9):1119-27
   PubMed Web of Science ®Google Scholar
• Gallant J, Parish M, Keruly J, Moore R. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40(8):1194-8
   PubMed Web of Science ®Google Scholar
• Cihlar T, Ray A, Laflamme G, Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007;12(2):267-72
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197(1):102-8
   PubMed Web of Science ®Google Scholar
• Gerard L, Chazallon C, Taburet A, Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antivir Ther 2007;12(1):31-39
   PubMed Web of Science ®Google Scholar
• Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005;19(1):93-5
   PubMed Web of Science ®Google Scholar
• Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses 2009;25(4):387-94
   PubMed Web of Science ®Google Scholar
• Tan L, Gilleece Y, Mandalia S, Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir. J Viral Hepat 2009;16(7):471-8
   PubMed Web of Science ®Google Scholar
• Van Rompay K, Brignolo L, Meyer D, Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004;48(5):1469-87
   PubMed Web of Science ®Google Scholar
• Buchacz K, Brooks J, Tong T, Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med 2006;7(7):451-6
   PubMed Web of Science ®Google Scholar
• Badiou S, de Boever CM, Terrier N, Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect 2006;52(5):335-8
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23(6):689-96
   PubMed Web of Science ®Google Scholar
• Nelson M, Katlama C, Montaner J, The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21(10):1273-81
   PubMed Web of Science ®Google Scholar
• Madeddu G, Bonfanti P, De Socio G, Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother 2008;62(1):6-11
   PubMed Web of Science ®Google Scholar
• Verhelst D, Monge M, Meynard JL, Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40(6):1331-3
   PubMed Web of Science ®Google Scholar
• Creput C, Gonzalez-Canali G, Hill G, Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003;17(6):935-7
   PubMed Web of Science ®Google Scholar
• Dupont C, Meier F, Loupy A, Acute renal failure and tenofovir: two new cases. Antivir Ther 2003;8(Suppl):76
   Google Scholar
• Schaaf B, Aries S, Kramme E, Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003;37(3):e41-3
   PubMed Web of Science ®Google Scholar
• Kapitsinou P, Ansari N. Acute renal failure in an AIDS patient on tenofovir: a case report. J Med Case Reports 2008;2:94
   Google Scholar
• Vallecillo-Sanchez G, Guelar-Grimberg A, Gonzalez-Mena A, Knobel-Freud H. Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection. Enferm Infecc Microbiol Clin 2008;26(5):316-17
   PubMed Web of Science ®Google Scholar
• Bpharm S, Talbot A, Trottier B. Acute renal failure in four HIV-infected patients: Potential association with tenofovir and nonsteroidal anti-inflammatory drugs. Can J Infect Dis Med Microbiol 2008;19(1):75-6
   PubMed Web of Science ®Google Scholar
• Ter Heine R, Huitema A, Jansen R, Prolonged exposure to tenofovir monotherapy 1 month after discontinuation because of tenofovir-related renal failure. Antivir Ther 2009;14(2):299-301
   PubMed Web of Science ®Google Scholar
• Wood S, Shah S, Steenhoff A, Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males. AIDS Patient Care STDs 2009:23(1):1-4
   PubMed Web of Science ®Google Scholar
• Callens S, De R, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect 2003;47(3):262-3
   PubMed Web of Science ®Google Scholar
• Peyriere H, Reynes J, Rouanet I, Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004;35(3):269-73
   PubMed Web of Science ®Google Scholar
• Williams J, Chadwick D. Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia. J Infect 2006;52(4):e107-8
   PubMedGoogle Scholar
• Mathew G, Knaus S. Acquired Fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med 2006;21(11):C3-5
   PubMed Web of Science ®Google Scholar
• Rifkin B, Perazella M. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004;117(4):282-4
   PubMed Web of Science ®Google Scholar
• Castrillo-Bustamante C, Vejo-Puente E, Velasco-Montes J, Hernandez-Hernandez JL. Severe hypokalemia and tenofovir. Enferm Infecc Microbiol Clin 2008;26(5):317-18
   PubMed Web of Science ®Google Scholar
• Earle K, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004;19(5):714-21
   PubMed Web of Science ®Google Scholar
• Di Biagio A, Rosso R, Monteforte P, Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. J Med Case Reports 2009;3:8136-9
   Google Scholar
• Irizarry-Alvarado J, Dwyer J, Brumble L, Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read 2009;19(3):114-21
   PubMed Web of Science ®Google Scholar
• Rollot F, Nazal EM, Chauvelot-Moachon L, Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003;37(12):e174-6
   PubMed Web of Science ®Google Scholar
• Coca S, Perazella M. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002;324(6):342-4
   PubMed Web of Science ®Google Scholar
• Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004;18(6):960-3
   PubMed Web of Science ®Google Scholar
• Parsonage M, Wilkins E, Snowden N, The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005;6(5):341-6
   PubMed Web of Science ®Google Scholar
• Zimmermann A, Pizzoferrato T, Bedford J, Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006;42(2):283-90
   PubMed Web of Science ®Google Scholar
• de la Prada F, Prados A, Tugores A, Acute renal failure and proximal renal tubular dysfunction in a patient with acquired immunodeficiency syndrome treated with tenofovir. Nefrologia 2006;26(5):626-30
   PubMed Web of Science ®Google Scholar
• Young B, Buchacz K, Baker R, ; HIV Outpatient Study Investigators. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the hiv outpatient study. J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6(3):178-87
   PubMedGoogle Scholar
• Gupta S. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008;22(2):99-103
   PubMed Web of Science ®Google Scholar
• Barrios A, Rendon A, Negredo E, Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005;19(6):569-75
   PubMed Web of Science ®Google Scholar
• Garcia-Benayas T, Rendon AL, Rodriguez-Novoa S, Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. AIDS Res Hum Retroviruses 2006;22(4):333-7
   PubMed Web of Science ®Google Scholar
• Barreiro P, Soriano V. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006;57(5):806-9
   PubMed Web of Science ®Google Scholar
• Ray A, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004;48(4):1089-95
   PubMed Web of Science ®Google Scholar
• Yarchoan R, Pluda J, Thomas R, Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336(8714):526-9
   PubMed Web of Science ®Google Scholar
• Lopez S, Negredo E, Garrabou G, Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. AIDS Res Hum Retroviruses 2006;22(1):33-9
   PubMed Web of Science ®Google Scholar
• Buchacz K, Young B, Baker R, Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort. J Acquir Immune Defic Syndr 2006;43(5):626-8
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20(5):711-18
   PubMed Web of Science ®Google Scholar
• Smith K, Weinberg W, De Jesus E, Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5:5
   PubMedGoogle Scholar
• Barditch-Crovo P, Deeks S, Collier A, Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-infected adults. Antimicrob Agents Chemother 2001;45(10):2733-9
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, D'Avolio A, Higher tenofovir plasma levels in patients with renal tubular damage [abstract 456]. In: 14th CROI, Montreal, Canada. February 2009
   Google Scholar
• Izzedine H, Hulot J, Villard E, Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194(11):1481-91
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, Soriano V, Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009;48(11):e108-16
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 2009;10(10):1675-85
   PubMed Web of Science ®Google Scholar
• Jones R, Stebbing J, Nelson M, Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 2004;37(4):1489-95
   PubMed Web of Science ®Google Scholar
• Woodward C, Hall A, Williams I, Tenofovir-associated renal and bone toxicity. HIV Med 2009;10(8):482-7
   PubMed Web of Science ®Google Scholar